Safety, pharmacokinetics, and sex hormone suppression of LY01021 versus relugolix: A single- and multiple-dose escalation study

Key Points

• LY01021 demonstrated a favorable safety profile compared to relugolix, indicating potential advantages.
• The study monitored pharmacokinetics and found that different dosing led to varying degrees of hormone suppression.
• Evaluation employed a single- and multiple-dose escalation design across multiple assessments over time.
• These findings support further trials to establish long-term safety and efficacy, highlighting the need for caution.